• Bloomberg

  • SHARE

Antibodies have become a familiar word in the pandemic era, perhaps suggesting they’re the best hope for keeping the deadly coronavirus at bay. But when crucial vaccine data was released this week, the spotlight panned to an unsung immune player: T cells.

AstraZeneca Plc, Pfizer Inc. and partner BioNTech SE, as well as China’s CanSino Biologics Inc. all hailed the presence of these white blood cells in vaccine recipients as a sign their experimental shots show promise.

In a time of both misinformation and too much information, quality journalism is more crucial than ever.
By subscribing, you can help us get the story right.

SUBSCRIBE NOW

PHOTO GALLERY (CLICK TO ENLARGE)